Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®

About this update from Medincell Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/38734b9ce7d4f810f9ca1efeabdf8a62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L35LTqGuXURwDyivUyd97w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/38734b9ce7d4f810f9ca1efeabdf8a62","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/BCq0_V5QHeUp6mEijvfjMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/38734b9ce7d4f810f9ca1efeabdf8a62","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, September 23, 2025--(BUSINESS WIRE)--Regulatory News:","length":74,"tagName":"p"},{"type":"text","content":"Medincell (Paris:MEDCL):","length":24,"tagName":"p"},{"type":"text","content":"Teva Canada Limited, a subsidiary of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI (Long-Acting Injectable) from Health Canada for the treatment of schizophrenia in adults1.","length":237,"tagName":"p"},{"type":"text","content":"Risperidone LAI formulated with Medincell’s proprietary technology is now approved in the United States, South Korea, and Canada.","length":129,"tagName":"p"},{"type":"text","content":"About Medincell","length":15,"tagName":"p"},{"type":"text","content":"Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.These treatments combine active pharmaceutical ingredients with our proprietary BEPO® technology, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.The first treatment based on BEPO® technology was approved for schizophrenia by the FDA in April 2023 and is now marketed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™).Our investi...

More updates from Medincell Sa